Latest post

Alan Stitt: “We need therapies fighting different hallmarks simultaneously”

PDR and DME are two manifestations of diabetic retinopathy (DR), and in many respects they stem from the same cause, explains professor Alan Stitt.

back of the eye diseases

“JETREA has a group of very loyal users worldwide”

Vinciane Vangeersdaele joined the Oxurion leadership team this past year. With extensive experience in commercializing pharmaceutical portfolios worldwide, including in ...

eye community

“Oxurion remains innovator in novel retinal therapies”

“There is currently an explosion in R&D activities in the retinal space. Numerous potential new therapies are ready for translation into clinical studies, making this a truly ...